Aim: Evaluations of nonalcoholic steatohepatitis (NASH) treatments require predicting
lifetime outcomes from short-term clinical trials. Materials & methods: A Markov model with NASH fibrosis stages F0–F3, NASH resolution, compensated cirrhosis
(F4/CC), ...